<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00218517</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-19246-1</org_study_id>
    <secondary_id>R21-19246-1</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT00218517</nct_id>
  </id_info>
  <brief_title>Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1</brief_title>
  <official_title>Selegiline for Treatment of Cannabis Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      During the past 15 years, the demand for treatment for marijuana-related problems in the&#xD;
      United States has increased nearly twofold. Selegiline is a medication currently used to&#xD;
      treat nicotine dependence. The purpose of this study is to evaluate whether selegiline may be&#xD;
      useful in treating individuals with marijuana dependence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Behavioral therapy paired with drug therapy might be a more effective treatment approach to&#xD;
      marijuana dependence than behavioral therapy alone. Selegiline is a monoamine oxidase-B&#xD;
      inhibitor. It increases dopamine activity in parts of the brain that are involved in&#xD;
      dependence on addictive drugs such as nicotine, cocaine, and marijuana. Selegiline has been&#xD;
      effective in treating nicotine dependence, but has not yet been studied in treating marijuana&#xD;
      dependent individuals. The purpose of this study is to evaluate the effectiveness of&#xD;
      selegiline in treating marijuana dependent individuals. Specifically, this study will&#xD;
      determine whether selegiline reduces marijuana craving and withdrawal symptoms, thus leading&#xD;
      to reduction or abstinence in marijuana use.&#xD;
&#xD;
      Participants in this 9-week, double-blind, placebo-controlled study will be randomly assigned&#xD;
      to receive either selegiline (10 mg/day in two 5 mg pills) or placebo. Study visits will&#xD;
      occur twice each week. At each study visit, participants will complete self-reports and urine&#xD;
      toxicology tests. Throughout the study, participants will receive weekly individual&#xD;
      counseling. The counseling sessions will last 15 minutes. Reduction in marijuana use as well&#xD;
      as the number of weeks of consecutive marijuana abstinence will be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Marijuana addiction severity, Week 9</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Marijuana withdrawl symptoms, Week 9</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Marijuana Abuse</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selegiline hydrochloride</intervention_name>
    <description>Daily oral selegiline, 5 mg po qd x 7 days, then 5 mg po bid for 7 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Selegiline, Selegiline hydrochloride, l-Deprenyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo capsules using blue 00 capsules</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meets DSM-IV criteria for current marijuana dependence&#xD;
&#xD;
          -  Positive urine toxicology test for marijuana&#xD;
&#xD;
          -  Reports current marijuana use&#xD;
&#xD;
          -  Weighs at least 100 lbs&#xD;
&#xD;
          -  Women of childbearing age will be included provided they agree to use adequate&#xD;
             contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Meets dependence or abuse criteria for alcohol&#xD;
&#xD;
          -  Meets dependence criteria for illicit substances other than marijuana&#xD;
&#xD;
          -  Serious medical disorders (such as unstable angina or liver failure), that may make&#xD;
             participation in the trial unsafe&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Currently diagnosed with a psychotic disorder&#xD;
&#xD;
          -  Currently suicidal or pose a homicidal risk&#xD;
&#xD;
          -  Currently taking over-the-counter (e.g., pseudoephedrine) or prescription (e.g.,&#xD;
             methylphenidate) sympathomimetic agents, antidepressant agents (e.g., tricyclic&#xD;
             antidepressants, serotonin reuptake inhibitors, bupropion, other monoamine oxidase&#xD;
             inhibitors), or meperidine (Demerol)&#xD;
&#xD;
          -  Unable to understand English&#xD;
&#xD;
          -  Known hypersensitivity to selegiline hydrochloride&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brent A Moore, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MRU</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>September 16, 2005</study_first_submitted>
  <study_first_submitted_qc>September 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <name_title>Ivan Montoya, Program Official</name_title>
    <organization>NIDA</organization>
  </responsible_party>
  <keyword>cannabis use disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selegiline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

